KINARUS THERAPEUTICS (SIX:KNRS)

kinarus-therapeutics-sixknrs-logo

Kinarus is a biopharmaceutical company that develops differentiated medicines in areas of stress related inflammatory processes based on cross disease area target assessment.

#People #Financial #Website #More

KINARUS THERAPEUTICS (SIX:KNRS)

Social Links:

Industry:
Biopharma Biotechnology Health Care Life Science Medical

Founded:
2017-09-01

Address:
Basel, Basel-Stadt, Switzerland

Country:
Switzerland

Website Url:
http://www.kinarus.com

Total Employee:
11+

Status:
Active

Contact:
+41 79 865 8969

Email Addresses:
[email protected]

Total Funding:
35.05 M CHF

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics



Current Advisors List

hari-kumar_image

Hari Kumar Chairman Of The Board @ Kinarus Therapeutics (SIX:KNRS)
Board_member
2021-03-01

eugene-tierney_image

Eugene Tierney Member of the Board of Directors @ Kinarus Therapeutics (SIX:KNRS)
Board_member
2017-09-01

alexander-bausch_image

Alexander Bausch Member of the Board of Directors @ Kinarus Therapeutics (SIX:KNRS)
Board_member
2017-09-01

viktor-boerlin_image

Viktor Boerlin Chief Development Advisor @ Kinarus Therapeutics (SIX:KNRS)
Advisor
2017-09-01

Current Employees Featured

thierry-fumeaux_image

Thierry Fumeaux
Thierry Fumeaux Chief Medical Officer @ Kinarus Therapeutics (SIX:KNRS)
Chief Medical Officer
2020-09-01

alexander-bausch_image

Alexander Bausch
Alexander Bausch CEO and Founder @ Kinarus Therapeutics (SIX:KNRS)
CEO and Founder
2017-09-01

urs-breitenstein_image

Urs Breitenstein
Urs Breitenstein Chief Financial Officer @ Kinarus Therapeutics (SIX:KNRS)
Chief Financial Officer
2017-09-01

claudia-berger_image

Claudia Berger
Claudia Berger Chief Clinical Development Officer @ Kinarus Therapeutics (SIX:KNRS)
Chief Clinical Development Officer
2017-09-01

matthew-wright_image

Matthew Wright
Matthew Wright Chief Operating Officer and Head of Research @ Kinarus Therapeutics (SIX:KNRS)
Chief Operating Officer and Head of Research
2017-09-01

corinne-peter_image

Corinne Peter
Corinne Peter Head of Project Management @ Kinarus Therapeutics (SIX:KNRS)
Head of Project Management
2017-09-01

Founder


alexander-bausch_image

Alexander Bausch

Stock Details


Company's stock symbol is SIX:KNRS

Investors List

yorkville-advisors_image

Yorkville Advisors

Yorkville Advisors investment in Post-IPO Debt - Kinarus Therapeutics (SIX:KNRS)

Official Site Inspections

http://www.kinarus.com

  • Host name: web4.tup.ch
  • IP address: 185.68.66.166
  • Location: Bettingen Switzerland
  • Latitude: 47.5704
  • Longitude: 7.6643
  • Timezone: Europe/Zurich
  • Postal: 4126

Loading ...

More informations about "Kinarus Therapeutics (SIX:KNRS)"

Kinarus Therapeutics (SIX:KNRS) - Crunchbase

Kinarus Therapeutics (SIX:KNRS) closed its last funding round on May 11, 2023 from a Post-IPO Equity round. Who are Kinarus Therapeutics (SIX:KNRS) 's competitors? Alternatives and possible competitors to Kinarus Therapeutics …See details»

Curatis

About Curatis. Curatis is a specialty pharmaceutical company based in Switzerland. “We focus on the acquisition, development and commercialisation of innovative medicines for the …See details»

Kinarus Company Profile 2024: Valuation, Investors, Acquisition

Kinarus General Information Description. Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and …See details»

CURATIS–KINARUS

§Kinarus AG remains in Liquidation Reverse Share Split §In the context of the Execution of the Business Combination, and subject to EGM approval, Kinarus Holding will execute a 4,480:1 …See details»

Curatis Company Presentation

Kinarus AG remains in liquidation Curatis AG offers to buy the Assets and Intellectual Property of Kinarus AG 100% I 1 Kinarus AG 100% I n Ongoing discussions for purchase of Assets and IP …See details»

Kinarus Therapeutics Group Reports 2022 Annual Results

May 31, 2023 Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, published …See details»

Kinarus Therapeutics (SIX:KNRS) - Funding, Financials, Valuation ...

Kinarus is focused on developing novel treatments for patients suffering from serious viral, respiratory, and ophthalmic diseases. Search Crunchbase. ... How much funding has this …See details»

Kinarus Company Profile - Office Locations, Competitors ... - Craft

Kinarus has 1 employees at their 1 location. See insights on Kinarus including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»

Courts of Basel-Stadt have revoked bankruptcy of Kinarus …

Feb 6, 2024 Kinarus Therapeutics Holding AG shall not be responsible for, or for investigating, any matter which is the subject of any statement, representation, warranty or covenant of …See details»

Kinarus Therapeutics Reports H1 2022 Financial Results and

Aug 31, 2022 Kinarus Therapeutics Holding AG Hochbergerstrasse 60C 4057 Basel, Switzerland +41 61 633 29 71 [email protected]: Investors & Media Chris Maggos …See details»

Kinarus, a Basel-Based Clinical-Stage Pharmaceutical Company

Jun 3, 2022 Kinarus reversely merged into Perfect Holding SA, which was listed on SIX Swiss Exchange since 1999. With an opening price of CHF 0.095 per share, the company achieved …See details»

Kinarus Therapeutics has decided to file for bankruptcy

Sep 25, 2023 Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland. The Kinarus team utilizes its …See details»

Kinarus Therapeutics Provides Strategic Update - GlobeNewswire

Nov 4, 2022 Kinarus Therapeutics Holding AG Hochbergerstrasse 60C 4057 Basel, Switzerland +41 61 633 29 71 [email protected]: Investors & Media Chris Maggos BioConfidant Sàrl +41 …See details»

Kinarus Therapeutics Group Reports 2022 Annual Results

May 31, 2023 Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland. The Kinarus team utilizes its …See details»

Kinarus Therapeutics Group Reports 2022 Annual Results

May 31, 2023 Kinarus Therapeutic Holding AG. Publishes Annual Report with Audited Consolidated Financial Results for Year Ended 31 December 2022. Clinical efforts re-focused …See details»

Kinarus Therapeutics Reports H1 2022 Financial Results and …

Basel, Switzerland, August 31, 2022 – Kinarus Therapeutics Holding AG (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ...See details»

Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and ...

Kinarus Therapeutic Holding AG. KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis model. Potential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF). …See details»

Kinarus Therapeutics initiates KIN001 Phase II KINFAST

Aug 29, 2022 Kinarus Therapeutics Holding AG Hochbergerstrasse 60C 4057 Basel, Switzerland +41 61 633 29 71 [email protected]: Investors & Media Chris Maggos …See details»

Kinarus Therapeutics Group Reports 2022 Annual Results

May 31, 2023 On 28 April 2023, Kinarus announced that the SIX Exchange Regulation ("SER") approved a deadline extension until the end of May 2023 for the publication of the Kinarus’ …See details»

Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity …

Dec 6, 2022 Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 Researchers at Friedrich-Alexander-Universität Erlangen …See details»

linkstock.net © 2022. All rights reserved